

<b>Examiner-Initiated Interview Summary</b>	<b>Application No.</b>	<b>Applicant(s)</b>	
	10/531,662	RATCLIFFE ET AL.	
	<b>Examiner</b>	<b>Art Unit</b>	
	ALEXANDER D. KIM	1656	

  

**All Participants:**

(1) ALEXANDER D. KIM.

(2) Mark D. Sweet.

**Date of Interview:** 2 November 2009

**Type of Interview:**

☒ Telephonic

☐ Video Conference

☐ Personal (Copy given to: ☐ Applicant    ☐ Applicant's representative)

Exhibit Shown or Demonstrated: ☐ Yes    ☐ No

If Yes, provide a brief description: \_\_\_\_\_

**Part I.**

Rejection(s) discussed:

NA

Claims discussed:

NA

Prior art documents discussed:

NA

**Part II.**

SUBSTANCE OF INTERVIEW DESCRIBING THE GENERAL NATURE OF WHAT WAS DISCUSSED:

*See Continuation Sheet*

**Part III.**

☐ It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview directly resulted in the allowance of the application. The examiner will provide a written summary of the substance of the interview in the Notice of Allowability.

☐ It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview did not result in resolution of all issues. A brief summary by the examiner appears in Part II above.

/Alexander D Kim/  
Examiner, Art Unit 1656

**Status of Application:** \_\_\_\_\_

(3) Sulay Jhaveri.

(4) \_\_\_\_\_

**Time:** \_\_\_\_\_

(Applicant/Applicant's Representative Signature – if appropriate)

Continuation of Substance of Interview including description of the general nature of what was discussed: The Examiner has noted following changes are required to the instant specification to remove any issues in regard to the sequence compliance: (A); the specification filed on 12/19/07, bottom, replace "SEQ ID NO: 2" to ---residues 6-14 of SEQ ID NO: 1---; (B) specification filed on 4/14/09 in table 2, description, replace "SEQ ID NOs 4-29" to ---SEQ ID NOs: 4-14, 16-17 and 19-29---; (C) amend the SEQ ID NO: 14 by adding the amino acid residues SEQ ID NO: 15 at the C-terminal of SEQ ID NO: 14; and amend SEQ ID NO: 17 by adding the residues of SEQ ID NO: 18 at the C-terminal end of SEQ ID NO: 17, because the amino acid residues shown in Table 2 are contiguous amino acids even though they are separated by gaps which were necessitated for the alignment. (D) add missing "Val Asn" in the C-terminal of SEQ ID NO: 31.